Inheritance of a germline mutation in one of the DNA mismatch repair genes predisposes human individuals to hereditary nonpolyposis colorectal cancer, characterized by development of tumors predominantly in the colon, endometrium, and gastrointestinal tract. Mice heterozygous for a mismatch repair-null mutation generally do not have an increased risk of neoplasia. However, mice constitutively lacking mismatch repair are prone to tumor development from an early age, particularly thymic lymphomas. Mismatch repair-deficient mice crossed to Apc +
Introduction
In mammalian cells, DNA mismatch repair is mediated by the proteins Msh2, Msh3, Msh6, Mlh1, Pms1, Pms2, and Mlh3. The initial recognition of mismatches in DNA is carried out by functional heterodimers of Msh2 bound with either Msh6 or Msh3, termed MutSa and MutSh, respectively (reviewed in ref. 1) . Following the binding of either MutSa or MutSh to a base mismatch in the DNA, recruitment of additional proteins facilitates completion of the repair process. Although MutSa has a preference for single base mismatches and MutSh preferentially binds to small loops, each heterodimer has some functional overlap (1) . Despite this overlap in function, in the absence of either Msh2 or Msh6, repair is severely compromised resulting in accumulation of excessive mutations (2) . Germline mutations in one or more of the human mismatch repair genes (i.e., hMSH2 or hMLH1) have been associated with the human disease hereditary nonpolyposis colorectal cancer (HNPCC). These individuals have a greatly increased lifetime risk of developing cancer of the colon, endometrium, and gastrointestinal tract. Greater than 90% of human HNPCC tumors show microsatellite instability, indicative of a loss of mismatch repair (3) (4) (5) (6) . This instability is associated with subsequent mutation of critical downstream genes, resulting in deregulated cell proliferation and tissue-specific tumorigenesis (reviewed in ref. 7) .
Although human HNPCC patients primarily develop cancers of the gastrointestinal tract, lymphomas and leukemias have been observed in certain kindreds (8, 9) . Analogous to the mouse models homozygous for a defect in mismatch repair, several human patients with germline mutations in both copies of any one of the mismatch repair genes, MLH1, MSH2, or PMS2, have presented with early-onset childhood T-or B-cell malignancies (10) (11) (12) (13) (14) (15) (16) .
In contrast to humans, mouse models genetically engineered to be haploinsufficient for any one of the mismatch repair genes generally do not show an increased risk of cancer whereas mice that are homozygous null for Msh2, Msh6, Mlh1, or Pms2 are prone to tumorigenesis (17) (18) (19) (20) (21) (22) . Mice deficient in Msh2 or Msh6 most commonly develop early-onset thymic lymphomas although other tumors such as ovarian and small intestinal tumors occur with a lower frequency (17, 19, 20) .
Immunohistochemistry with T-and B-cell markers, as well as histology, showed that murine mismatch repair-deficient thymic lymphomas are very homogeneous (23) . These lymphomas are predominantly of T-cell origin, characterized by a ''starry sky'' appearance, enlarged nuclei, reduced cytoplasm, and numerous mitotic figures (17) . Hematopoietic development appears normal in the Msh2-null mice (17) . Msh2-deficient thymic lymphomas are thought to represent a single histopathologic entity and the tumor homogeneity suggests specific recurring genetic events may underlie the lymphocyte transformation and expression of a malignant phenotype.
In Msh2-deficient mice the onset of thymic lymphomas begins at 2 months of age and in Msh6-deficient mice tumor onset begins at 9 months; 50% survival times are 5 and 9 months, respectively (17, 19) . The spontaneous tumor spectrum of Msh2, Msh3, Msh6, and Mlh1 null mice has been altered by breeding these mice to Apc +/À /Min mice resulting in increased intestinal tumor incidence, intestinal tumor multiplicity per animal, and reduced survival (24) (25) (26) . This led us to believe that the spontaneous tumor spectrum of Msh2-and Msh6-deficient mice may be shifted by breeding them to athymic nude mice. We hypothesized that Msh2-and Msh6-deficient mice succumb to thymic lymphomas before the development of other cancers such as colonic tumors. We tested our hypothesis by breeding Msh2-and Msh6-deficient mice to athymic nude mice to determine if these mice would develop a tumor spectrum similar to the human HNPCC tumor spectrum and provide us with a novel mouse model.
The nude phenotype is characterized by a loss-of-function mutation in the Foxn1 gene ( forkhead box N1), a winged helix/ forkhead transcription factor, which results in abnormal morphogenesis of the epidermis, hair follicles, and thymus (27) . Without Foxn1 expression, there is a basic defect in development of the embryonic ectoderm resulting in the absence of a thymus and these mice cannot properly attract hematopoeitic precursor cells essential for T-cell development. Consequently, they have severely reduced numbers of immature and mature T-cells and are therefore immunocompromised (28) . Nude mice do have a minimal amount of extra-thymic T-cell maturation occurring in such organs as the spleen (29) 
Materials and Methods
Genotyping. Msh2 mice (17) nu/nu mice. Msh6 genotyping was carried out using earclip DNA as previously described (19) . Msh2 genotyping was carried out using a PCR assay with earclip DNA and the following three primers: U771 forward (5V-GCTCACTTAGACGCCATTGT-3V) and L926 reverse (5V-AAAG-TGCACGTCATTTGGA-3V) amplifying the wild-type allele and U771 forward and neo reverse (5V-TGG AAG GAT TGG AGC TAC GG-3V) amplifying the targeted allele. The nude phenotype is the result of a single base pair deletion mutation in the Foxn1 gene that when present in the homozygous state leads to the nude phenotype (27) . Genotyping of the Foxn1 gene was done using earclip DNA as described (30) . Briefly, modified PCR primers were used to introduce an artificial restriction site in the Foxn1 gene PCR product based on the presence or absence of the nude mutation. Subsequently, PCR-RFLP analysis was carried out to distinguish between heterozygous (Foxn1 +/nu ) and wild-type (Foxn1 +/+ ) mice. Examination of mice. The mouse experimental protocol was approved by the Health Science Animal Policy and Welfare Committee of the University of Alberta, and all animals cared for according to the guidelines of the Canadian Council on Animal Care. Mice were monitored daily for signs of poor health/grooming or tumorigenesis. Mice were sacrificed by isoflurane overdose on signs of lethargy, weight loss, or physical demonstration of a tumor. Murine tissues were fixed in 10% buffered formalin and embedded in paraffin blocks. Tumor and control brain tissue were frozen at À80jC for DNA analysis. Histologic analysis was done on 5 Am sections stained with H&E using standard methods (P.N. ;Foxn1Foxn1 nu/nu mice and were analyzed for microsatellite instability. DNA was extracted using Qiaquick DNA extraction columns (Qiagen, Inc., Valencia, CA). Microsatellite loci were amplified using fluorescently labeled Licor PCR primers and products were analyzed on a Licor electrophoresis gel system (LicorBiosciences, Lincoln, NE). Ten loci were investigated for microsatellite status using primers as follows: (a) five primer pairs used amplified mononucleotide repeats: JH101, JH102, JH103, JH104 (19) , and U12235 (5V GCTCATCTTCGTTCCCTGTC-3V and 5V-CATTCGGTGGAAAGCTCTGA-3V; ref. 
Results

Msh2
À À À/ /À À À ;Foxn1 nu/ /nu and Msh6 with a median survival time to tumorigenesis of 11 months compared with 9 months in the Msh6 À/À ;Foxn1 nu/nu ; P = 0.007. At 9 months of age only 46% of the Msh6
nu/nu mice were still alive whereas 60% of the Msh6 À/À mice were still alive. By 12 months of age only 12.5% of the Msh6
nu/nu mice were alive, however, 35% of the Msh6 À/À mice were still alive.
Although the genetic background of the two mouse models was not identical (the Msh6 À/À mice were on a C57BL/6 background and the Msh6 À/À ;Foxn1 nu/nu mice were on a C57BL/6/Balb/C background), different genetic backgrounds of Msh6 À/À mice had previously been determined to have no effect on spontaneous survival of the mice. 3 Second, a Kaplan-Meier survival curve was generated comparing death due to tumorigenic causes in Msh6 mice presented with clearly visible s.c. tumors commonly appearing on the neck and chest region. H&E staining showed many of these tumors to be lymph nodes that had undergone general infiltration and replacement by malignant lymphocytes. However, in several cases the precise tissue of origin could not be identified due to the destruction of tissue structure by malignant cells (Fig. 2) . Widespread tumor ;Foxn1 nu/nu mice. Life span of the mice and cause of death were recorded and Kaplan-Meier survival curves were generated using the R statistical analysis software package version 1. infiltration into major organs was found to have occurred in the majority of mice. Organs commonly infiltrated by tumor cells include the liver, spleen, kidney, heart, and colon. In the liver and spleen there was sinusoidal tumor infiltrate as well as perivascular infiltrate (Fig. 2C) . Dissemination to the heart occurred in several mice as well, and although the myocardium itself was normal, there was an infiltrate of tumor cells in the adventitia of the aorta and associated nerves. Tumor masses were composed of a uniform population of quite immature lymphocytes and presented with the signature ''starry sky'' appearance due to the scattered tingible body macrophages (Fig. 2B) mice were sacrificed at 24 days, 8 weeks, and 3 months of age and each colon was divided into three sections. Three mice for each age group were used to account for individual variation between mice. In all colon sections examined there were no unusual cellular changes or thickening of the epithelial cell wall. We found no evidence of cellular hyperproliferation or precancerous lesions in the colon and conclude that the colon is not susceptible to tumor formation in these mice. Lymphoblastic lymphoma immunohistochemistry characterization. To further characterize the tumors arising in the Msh6 À/À ;Foxn1 nu/nu mice, we did immunohistochemistry using several antibodies on eight lymphoblastic lymphomas and one squamous cell tumor (Tables 1 and 2 ). The Msh6 À/À ;Foxn1 nu/nu tumors were stained with CD45 (leukocyte common antigen), a marker found on hematopoietic cells with higher expression in lymphocytes then leukocytes (35) . One of the eight Msh6 À/À ;Foxn1
nu/nu lymphoblastic lymphomas tested showed weak positive staining (<10% of cells staining positive). The remaining seven tumors tested were negative (Fig. 3E) . Negative staining for CD45 leads us to suggest that the lymphoblastic lymphomas arising in these mice are arrested at a very early stage in differentiation, having arisen before the expression of CD45. Tumors were stained with Ki67, a nuclear protein expressed in proliferating cells but absent in resting cells. Positive Ki67 staining in all nine tumors tested indicates a high proliferation index, leading us to conclude that these tumors were rapidly growing (Fig. 3F) . To determine if the lymphoblastic lymphomas were T-or B-cell in origin, we stained the tumors with CD3 (T-cell-specific marker) and B220 (B-cell-specific marker, also known as CD45R). None of the tumors tested stained positive for CD3 (Table 2 ). Only two were positive for B220 ( Table 2 ). Tumors were then stained with Pax5, a very early marker specific for the B-cell lineage (36) . The Pax5 protein (also known as B-cell-specific activator protein) is a transcription factor expressed in the earliest B-cell precursors and, once activated, causes a cascade of other genes to be turned on and the cell to develop along the B-cell lineage (36) . All of the Msh6 À/À ;Foxn1 nu/nu lymphoblastic lymphomas tested were Pax5 positive, indicating these tumors were early B-cell in origin ( Fig. 3F and G Microsatellite instability analysis of lymphoblastic lymphomas. Two dinucleotide repeat microsatellite markers were used previously to investigate the presence of microsatellite instability in six Msh2 À/À mice (17) . Whereas normal tissues from the Msh2 À/À mice were stable, all lymphomas and tumorinfiltrated organs displayed novel allele sizes at one or both of the loci tested (17) . We therefore hypothesized that Msh2 À/À ;Foxn1 nu/nu lymphoblastic lymphomas would also display high levels of microsatellite instability. Using five Msh2 À/À ;Foxn1 nu/nu lymphoblastic lymphomas from five different mice, we investigated the stability of microsatellite sequences at 10 loci. Five primer pairs analyzed mononucleotide repeats; three primer pairs analyzed dinucleotide repeats; one primer pair analyzed a trinucleotide repeat; and one primer pair analyzed a tetranucleotide repeat. The size of the PCR product from tumor DNA was compared with the size of the PCR product from normal matched brain DNA. Tumors were considered microsatellite unstable low if 1 or 2 markers of 10 tested showed instability. Tumors were considered microsatellite unstable high if 3 or more markers of 10 tested showed instability. All tumors tested showed instability in at least one marker tested and were classified as microsatellite unstable. Two of five tumors tested showed instability at one or two markers and were classified as microsatellite unstable low whereas three of five tumors tested showed instability at greater than three markers tested and were classified as microsatellite unstable high. Overall, there were 14/ 50 unstable reactions corresponding to 28% instability.
Discussion
As mismatch repair is thought to have a ubiquitous role in DNA repair and mutation avoidance, the tissue specificity of tumorigenesis in human HNPCC patients as well as in mismatch repair-deficient mice is unexpected. In contrast to the gastrointestinal tumors that develop in human HNPCC patients, mismatch repair-deficient mice develop predominately thymic lymphomas.
We hypothesized that mismatch repair-deficient mice succumb to tissue-specific lymphomagenesis at too young an age to allow for the development of a tumor spectrum similar to human HNPCC patients. If mice are prevented from or delayed in developing lymphomas, they may develop gastrointestinal tumors similar to human HNPCC patients and therefore present as a new model with which to study mismatch repair-deficient gastrointestinal tumor development. To test this hypothesis, we bred Msh2-and Msh6-deficient mice to athymic nude mice. We have shown that breeding Msh2-and Msh6-deficient mice onto an athymic nude background promotes the development of predominantly B-cell lymphoblastic lymphomas. Moreover, these lymphomas arise from a pre-B-cell lineage at an early age, starting at 6.5 weeks of age. Thus, mice lacking mismatch repair seem destined to develop hematologic malignancy, even in the absence of a thymus and a greatly reduced T-cell component.
The median time to tumorigenesis in the Msh2 À/À ;Foxn1 nu/nu mice, 5.5 months, was not altered compared with the Msh2
mice. This is in contrast to our original expectation that mice would live longer when prevented from developing thymic lymphomas. We propose that mismatch repair plays a crucial role in the development of hematologic cells and, in its absence, these cells are prone to malignant transformation. In contrast to the Msh2 À/À ;Foxn1 nu/nu mice, the Msh6 À/À ;Foxn1 nu/nu mice have reduced survival time to tumorigenesis (median survival, 8.9 months) compared with the Msh6 À/À mice (median survival, 11 months). The earlier age of onset of Msh6 À/À ;Foxn1 nu/nu malignancies may be due to differences in genetic background between the Msh6;Foxn1 and Msh6 animals although work by Edelmann 4 would suggest that genetic background differences have no effect on the survival of Msh6 À/À animals. The loss of the FOXN1 transcription factor may contribute to neoplasia in mice. Mismatch repair-deficient mice treated with genotoxic exposure have accelerated onset of lymphogenesis (37) (38) (39) , also supporting the idea that in the constitutive absence of mismatch repair, mice are poised to develop predominantly hematologic malignancies, whether spontaneous or induced.
Although not seen macroscopically, early lesions in the colon may be occurring in the Msh2 À/À ;Foxn1 nu/nu and Msh6 À/À ;Foxn1 nu/nu mice. This would indicate that cellular changes are in fact altering the epithelium in the colon but that mice are succumbing to lymphomagenesis before further development of the colonic lesions. However, we found no cellular differences suggestive of a hyperproliferative or altered state in any of the colons studied regardless of age or region of colon investigated, leading us to suggest that mismatch repair-deficient nude mice are not prone to colonic lesions. The continued development of lymphomas and the absence of intestinal malignancies in Msh2 À/À ;Foxn1 nu/nu and Msh6 À/À ;Foxn1 nu/nu mice support the idea that mismatch repair is involved in the maintenance of hematologic cells.
Mismatch repair-deficient thymic lymphomas have been shown to comprise a single histopathologic entity derived from normal hematopoietic progenitors (17, 19) . Thymic lymphomas from Msh2 À/À mice closely resemble human precursor T-cell lymphoblastic lymphomas (23) . Histologic examination of lymphomas from both Msh2 À/À ;Foxn1 nu/nu and Msh6 À/À ;Foxn1 nu/nu mice revealed a ''starry sky'' appearance and numerous mitotic figures indistinguishable from Msh2 À/À thymic lymphomas. From this we suggest that similar underlying molecular pathways leading to tumorigenesis occur in these mismatch repair-deficient mouse models. This supports a role for mismatch repair in maintaining the genomic integrity of hematologic cell types and suggests that the absence of mismatch repair is associated with the accumulation of mutations in key tumor suppressor and oncogenes and the development of hematologic malignancies.
Of the 23 Msh2 À/À thymic lymphomas in the literature that have been immunophenotyped, 22 of 23 express CD3, demonstrating their derivation from precursor T-cells (17, 23) . Of the eight Msh6 À/À lymphomas that have been immunophenotyped, five of eight are B-cell in origin and only three of eight are T-cell in origin (19) . This may suggest a propensity for mice lacking Msh6 to develop B-cell malignancies whereas mice lacking Msh2 develop T-cell malignancies. If mice lacking Msh6 are indeed prone to develop B-cell malignancies, then it is not surprising that Msh6 À/À ;Foxn1 nu/nu mice rapidly develop B-cell lymphoblastic lymphomas.
Only one of the Msh6 À/À ;Foxn1 nu/nu lymphoblastic lymphomas stained positive for the marker CD45, confirming it was lymphoid in origin. Negative staining in seven of the eight tumors tested, however, suggested that these tumors were very early in development and did not yet present with the CD45 marker. B-cell development is characterized by the rearrangement and expression of immunoglobulin heavy and light chain genes. The first immunoglobulin gene rearrangement (occurring during the early pro-B-cell stage) is the joining of D H (diversity) gene elements to J H (joining) gene elements, followed in the late pro-B-cell stage by V H (variable) to D H J H joining. B220 (CD45R in humans) is a cell surface B-cell marker expressed in early pro-B-cells before or in conjugation with D H to J H gene rearrangement. After staining of the Msh6 À/À ;Foxn1 nu/nu tumors found them to be B220 negative as well as CD3 negative, we investigated for the presence of Pax5. Negative staining for B220 and positive staining for Pax5 indicates that the majority of lymphoblastic lymphomas arising in Msh6 À/À ;Foxn1 nu/nu mice are very early B-cell in origin. We hypothesized that these tumors are likely to be arrested in B-cell development before D H to J H joining. Surprisingly, we found all but one of the tumors showed some degree of D H to J H rearrangements, suggesting that B-cell development is abnormal in these tumors. It is possible that in the absence of mismatch repair, B-cell immunoglobulin gene rearrangement is incorrectly regulated, leading to tumorigenesis. We did find, however, that no particular class of D H or J H elements was overrepresented, suggesting that no particular element is responsible for the abnormal regulation. Further investigation for the presence of V H to DJ H rearrangements may help determine the precise stage of development at which these lymphoblastic lymphomas arise.
We hypothesized that Msh2 À/À ;Foxn1 nu/nu lymphoblastic lymphomas would display a high degree of microsatellite instability, an indication of a high level of overall genomic instability. All tumors tested showed microsatellite instability. Instability was seen almost exclusively in mono-and dinucleotide repeats; instability was negligible in the trinucleotide marker tested and nonexistent in the tetranucleotide marker tested. Particular mononucleotide markers (JH101, JH103, and U12235) and dinucleotide markers (D1mit83 and D7mit17) showed greater levels of instability than comparable markers, suggesting that some and not all microsatellites are informative when assaying for microsatellite instability. In addition, the length of a microsatellite may play a role in its susceptibility to instability. In Msh2 À/À ;Foxn1 nu/nu lymphoblastic lymphomas, instability was not seen in the shorter mononucleotide repeats (JH102 and JH104, 8 and 10 bp, respectively) but was seen in the longer mononucleotide repeats (JH103 and U12335, 13 and 24 bp, respectively). Due to the lack of microsatellite instability seen in Msh6 À/À tumor cells (19) , likely due to the redundancy of Msh6 and Msh3 in forming a functional MutL heterodimer, microsatellite instability was not tested in tumors arising in Msh6 À/À ;Foxn1 nu/nu mice. In contrast to HNPCC patients with heterozygous mismatch repair mutations, patients with homozygous mutations in mismatch repair genes present with early-onset T-or B-cell malignancies. From this we suggest that the effect of a loss of mismatch repair is highly dependent on when in development loss of mismatch repair occurs. For example, constitutive loss of mismatch repair in either mice or humans leads to a predisposition to develop hematologic cancers. Alternatively, in HNPCC, loss of the wild-type allele that results in loss of mismatch repair occurs in specific tissues later in life. Those tissues, such as the colon, may be those with higher exposure to exogenous DNA damaging agents and may therefore result in a different tumor spectrum.
Previous reports have suggested that thymic lymphomas predominate in mismatch repair-deficient mice due to the high turnover of developing T-cells in the thymus and subsequent accumulation of mutations in key downstream genes (20, 40) . Our finding that mismatch repair-deficient mice develop hematologic malignancies even in the absence of a thymus leads us to suggest that malignant transformation is independent of cell turnover rate. Altered mismatch repair gene expression, mismatch repair gene mutation, and/or microsatellite instability has been observed in varying proportions of human hematologic neoplasms, consistent with the idea that loss of mismatch repair has a significant role in human hematologic malignancy (41) (42) (43) (44) (45) .
We have previously reported that constitutive loss of MSH2 in a human patient leads to T-cell acute lymphocytic leukemia and features consistent with neurofibromatosis type 1 (16) . Recently, this patient developed B-cell lymphoma. This parallels the B-cell malignancies seen in the Msh2 À/À ;Foxn1 nu/nu and Msh6 À/À ;Foxn1 nu/nu mice and further strengthens our conclusions that mismatch repair plays an important role in the development of T-and B-cells. Our results support the hypothesis that mismatch repair has a key role in developing T-and B-cells. We implicate mismatch repair as an important repair mechanism in normal T-and B-cell development.
